Breaking News, Collaborations & Alliances

CureVac, Crucell in Flu Vax Development Pact

To develop a vaccine based on RNActive technology

CureVac has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. under which CureVac will collaborate with Crucell Holland B.V. (a Janssen Pharmaceutical member company) on the development of an flu vaccine based on CureVac’s RNActive technology. CureVac’s technology platform with RNActive vaccines has demonstrated effectiveness and safety in several clinical trials.
 
CureVac will develop optimized RNActive vaccines based on Crucell’s proprietary antigen sequences, which will be tested in various models. Additional details were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters